The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
Phyllis I Spuls - One of the best experts on this subject based on the ideXlab platform.
-
domino doxycycline 40 mg vs Minocycline 100 mg in the treatment of rosacea a randomized single blinded noninferiority trial comparing efficacy and safety
British Journal of Dermatology, 2017Co-Authors: M. Van Der Linden, A R Van Ratingen, D C Van Rappard, Stella A. Nieuwenburg, Phyllis I SpulsAbstract:SummaryBackground There is a lack of evidence for Minocycline in the treatment of rosacea. Objectives To compare the efficacy and safety of doxycycline 40 mg vs. Minocycline 100 mg in papulopustular rosacea. Methods In this randomized, single-centre, 1 : 1 allocation, assessor-blinded, noninferiority trial, patients with mild-to-severe papulopustular rosacea were randomly allocated to either oral doxycycline 40 mg or Minocycline 100 mg for a 16-week period with 12 weeks of follow-up. Our primary outcomes were the change in lesion count and change in patient's health-related quality of life (using RosaQoL). Intention-to-treat and per protocol analyses were performed. Results Of the 80 patients randomized (40 Minocycline, 40 doxycycline), 71 were treated for 16 weeks. Sixty-eight patients completed the study. At week 16, the median change in lesion count was comparable in both groups: doxycycline vs. Minocycline, respectively 13 vs. 14 fewer lesions. The RosaQoL scores were decreased for both doxycycline and Minocycline, respectively by 0·62 and 0·86. Secondary outcomes were comparable except for Investigator's Global Assessment success, which was seen significantly more often in the Minocycline group than in the doxycycline group (60% vs. 18%, P < 0·001). At week 28, outcomes were comparable, except for RosaQoL scores and PaGA, which were significantly different in favour of Minocycline (P = 0·005 and P = 0·043, respectively), and fewer relapses were recorded in the Minocycline group than in the doxycycline group (7% and 48%, respectively; P < 0·001). No serious adverse reactions were reported. Conclusions Minocycline 100 mg is noninferior to doxycycline 40 mg in efficacy over a 16- week treatment period. At follow-up, RosaQoL and PaGA were statistically significantly more improved in the Minocycline group than in the doxycycline group, and Minocycline 100 mg gives longer remission. In this study there was no significant difference in safety between these treatments; however, based on previous literature Minocycline has a lower risk-to-benefit ratio than doxycycline. Minocycline 100 mg may be a good alternative treatment for those patients who, for any reason, are unable or unwilling to take doxycycline 40 mg.
-
DOMINO, doxycycline 40 mg vs. Minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety
2017Co-Authors: Van Der Linden M. M. D., Van Ratingen A. R., Van Rappard D. C., Nieuwenburg S. A., Phyllis I SpulsAbstract:Background There is a lack of evidence for Minocycline in the treatment of rosacea. Objectives To compare the efficacy and safety of doxycycline 40 mg vs. Minocycline 100 mg in papulopustular rosacea. Methods In this randomized, single-centre, 1 : 1 allocation, assessor-blinded, noninferiority trial, patients with mild-to-severe papulopustular rosacea were randomly allocated to either oral doxycycline 40 mg or Minocycline 100 mg for a 16-week period with 12 weeks of follow-up. Our primary outcomes were the change in lesion count and change in patient's health-related quality of life (using RosaQoL). Intention-to-treat and per protocol analyses were performed. Results Of the 80 patients randomized (40 Minocycline, 40 doxycycline), 71 were treated for 16 weeks. Sixty-eight patients completed the study. At week 16, the median change in lesion count was comparable in both groups: doxycycline vs. Minocycline, respectively 13 vs. 14 fewer lesions. The RosaQoL scores were decreased for both doxycycline and Minocycline, respectively by 0.62 and 0.86. Secondary outcomes were comparable except for Investigator's Global Assessment success, which was seen significantly more often in the Minocycline group than in the doxycycline group (60% vs. 18%, P
Tsuyoshi Miyaoka - One of the best experts on this subject based on the ideXlab platform.
-
Minocycline as adjunctive therapy for patients with unipolar psychotic depression an open label study
Progress in Neuro-psychopharmacology & Biological Psychiatry, 2012Co-Authors: Tsuyoshi Miyaoka, Rei Wake, Motohide Furuya, Kristian Liaury, Masa Ieda, Kazunori Kawakami, Keiko Tsuchie, Michiyo Taki, Kotomi Ishihara, Tomoko ArakiAbstract:Abstract Background Approximately 25% of patients admitted to a hospital as a result of depression are actually suffering from psychotic depression. Psychotic symptoms can be present in patients with either unipolar depression or bipolar depression and can be difficult to treat. It was reported the second-generation tetracycline may exert potential antidepressant effects through its robust neuroprotective activities, which include neurogenesis, antioxidation, and anti-glutamate excitotoxicity, and may direct regulation of pro-inflammatory agents. Methods This was a 6-week, open-label study to evaluate the efficacy and safety of Minocycline in combination with antidepressants in adult inpatients (n = 25) diagnosed with major depression with psychotic features (psychotic depression) according to DSM-IV-TR. The primary endpoint was the change from baseline in the Hamilton Depression Rating Scale (HAM-D-21) score from baseline to week 6. Secondary endpoints were changes in the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression (CGI) Scale scores from baseline to week 6. Spontaneously reported adverse events were recorded. Results The patients' average age was 46.9 ± 10.2 years. Minocyline (150 mg/day) in combination with antidepressants (fulvoxamine, paroxetine, and sertraline) provided significant improvement in depression. Mean (± SD) HAM-D-21 was reduced to 6.7 ± 1.9 at week 6 from a baseline value of 40.4 ± 2.5. Significant improvement of psychotic symptoms (mean ± SD) was indicated by the decrease in BPRS scores from baseline (63.3 ± 8.7) to week 6 (4.6 ± 2.4). No serious adverse events occurred. Conclusions These preliminary data suggest that Minocycline in combination with antidepressants is effective and well tolerated in the treatment of unipolar psychotic depression. Further studies using larger, double-blind, parallel-group design are warranted to confirm these findings.
-
Minocycline for Schizophrenia: A critical review
Open Journal of Psychiatry, 2012Co-Authors: Tsuyoshi MiyaokaAbstract:Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestoractive or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntington’s disease, amyotrophic lateral sclerosis and Parkinson’s disease. Despite controversies about its efficacy, the relative safety and tolerability of Minocycline have led to the launching of various clinical trials. Previously, we reported the antipsychotic effects of Minocycline in patients with schizophrenia. In a pilot investigation, we administered Minocycline as an open-label adjunct to antipsychotic medication to patients with schizophrenia. The results of this trial suggested that Minocycline might be a safe and effective adjunct to antipsychotic medications, and that augmentation with Minocycline may prove to be a viable strategy for “boosting” antipsychotic efficacy and for treating schizophrenia. Recently, in randomized double-blind placebo-controlled clinical trials, the addition of Minocycline to treatment as usual early in the course of schizophrenia predominantly improves negative symptoms. The present review summarizes the available data supporting the clinical testing of Minocycline for patients with schizophrenia. In addition, we extend our discussion to the potential applications of Minocycline for combining this treatment with cellular and molecular therapy.
-
Clinical potential of Minocycline for schizophrenia.
CNS & neurological disorders drug targets, 2008Co-Authors: Tsuyoshi MiyaokaAbstract:Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. In particular, it has been shown to delay motor alterations, inflammation and apoptosis in models of Huntington's disease, amyotrophic lateral sclerosis and Parkinson's disease. Despite controversies about its efficacy, the relative safety and tolerability of Minocycline have led to various clinical trials. Recently, we reported the antipsychotic effects of Minocycline in patients with schizophrenia. In a pilot investigation, we administered Minocycline as an open-label adjunct to antipsychotic medication to patients with schizophrenia. The results of this trial suggested that Minocycline might be a safe and effective adjunct to antipsychotic medications, and that augmentation with Minocycline may prove to be a viable strategy for "boosting" antipsychotic efficacy and for treating schizophrenia. The present review summarizes the available data supporting the clinical testing of Minocycline for patients with schizophrenia. In addition, we extend our discussion to the potential applications of Minocycline for combining this treatment with cellular and molecular therapy.
-
Possible antipsychotic effects of Minocycline in patients with schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry, 2006Co-Authors: Tsuyoshi Miyaoka, Rei Yasukawa, Hideaki Yasuda, Maiko Hayashida, Takuji Inagaki, Jun HoriguchiAbstract:We present two cases of patients with schizophrenia treated with Minocycline. Minocycline (a second-generation tetracycline) is an established and safe broad-spectrum antibiotic that crosses the blood-brain barrier, with additional efficacy for diseases such as acne and rheumatoid arthritis. Animal studies have suggested that Minocycline may prevent progression of some neurological disorders. Moreover, it has been reported that Minocycline might have antidepressant effects. We report two cases of acute schizophrenia with predominant catatonic symptoms that responded to Minocycline.
M. Van Der Linden - One of the best experts on this subject based on the ideXlab platform.
-
domino doxycycline 40 mg vs Minocycline 100 mg in the treatment of rosacea a randomized single blinded noninferiority trial comparing efficacy and safety
British Journal of Dermatology, 2017Co-Authors: M. Van Der Linden, A R Van Ratingen, D C Van Rappard, Stella A. Nieuwenburg, Phyllis I SpulsAbstract:SummaryBackground There is a lack of evidence for Minocycline in the treatment of rosacea. Objectives To compare the efficacy and safety of doxycycline 40 mg vs. Minocycline 100 mg in papulopustular rosacea. Methods In this randomized, single-centre, 1 : 1 allocation, assessor-blinded, noninferiority trial, patients with mild-to-severe papulopustular rosacea were randomly allocated to either oral doxycycline 40 mg or Minocycline 100 mg for a 16-week period with 12 weeks of follow-up. Our primary outcomes were the change in lesion count and change in patient's health-related quality of life (using RosaQoL). Intention-to-treat and per protocol analyses were performed. Results Of the 80 patients randomized (40 Minocycline, 40 doxycycline), 71 were treated for 16 weeks. Sixty-eight patients completed the study. At week 16, the median change in lesion count was comparable in both groups: doxycycline vs. Minocycline, respectively 13 vs. 14 fewer lesions. The RosaQoL scores were decreased for both doxycycline and Minocycline, respectively by 0·62 and 0·86. Secondary outcomes were comparable except for Investigator's Global Assessment success, which was seen significantly more often in the Minocycline group than in the doxycycline group (60% vs. 18%, P < 0·001). At week 28, outcomes were comparable, except for RosaQoL scores and PaGA, which were significantly different in favour of Minocycline (P = 0·005 and P = 0·043, respectively), and fewer relapses were recorded in the Minocycline group than in the doxycycline group (7% and 48%, respectively; P < 0·001). No serious adverse reactions were reported. Conclusions Minocycline 100 mg is noninferior to doxycycline 40 mg in efficacy over a 16- week treatment period. At follow-up, RosaQoL and PaGA were statistically significantly more improved in the Minocycline group than in the doxycycline group, and Minocycline 100 mg gives longer remission. In this study there was no significant difference in safety between these treatments; however, based on previous literature Minocycline has a lower risk-to-benefit ratio than doxycycline. Minocycline 100 mg may be a good alternative treatment for those patients who, for any reason, are unable or unwilling to take doxycycline 40 mg.
A R Van Ratingen - One of the best experts on this subject based on the ideXlab platform.
-
domino doxycycline 40 mg vs Minocycline 100 mg in the treatment of rosacea a randomized single blinded noninferiority trial comparing efficacy and safety
British Journal of Dermatology, 2017Co-Authors: M. Van Der Linden, A R Van Ratingen, D C Van Rappard, Stella A. Nieuwenburg, Phyllis I SpulsAbstract:SummaryBackground There is a lack of evidence for Minocycline in the treatment of rosacea. Objectives To compare the efficacy and safety of doxycycline 40 mg vs. Minocycline 100 mg in papulopustular rosacea. Methods In this randomized, single-centre, 1 : 1 allocation, assessor-blinded, noninferiority trial, patients with mild-to-severe papulopustular rosacea were randomly allocated to either oral doxycycline 40 mg or Minocycline 100 mg for a 16-week period with 12 weeks of follow-up. Our primary outcomes were the change in lesion count and change in patient's health-related quality of life (using RosaQoL). Intention-to-treat and per protocol analyses were performed. Results Of the 80 patients randomized (40 Minocycline, 40 doxycycline), 71 were treated for 16 weeks. Sixty-eight patients completed the study. At week 16, the median change in lesion count was comparable in both groups: doxycycline vs. Minocycline, respectively 13 vs. 14 fewer lesions. The RosaQoL scores were decreased for both doxycycline and Minocycline, respectively by 0·62 and 0·86. Secondary outcomes were comparable except for Investigator's Global Assessment success, which was seen significantly more often in the Minocycline group than in the doxycycline group (60% vs. 18%, P < 0·001). At week 28, outcomes were comparable, except for RosaQoL scores and PaGA, which were significantly different in favour of Minocycline (P = 0·005 and P = 0·043, respectively), and fewer relapses were recorded in the Minocycline group than in the doxycycline group (7% and 48%, respectively; P < 0·001). No serious adverse reactions were reported. Conclusions Minocycline 100 mg is noninferior to doxycycline 40 mg in efficacy over a 16- week treatment period. At follow-up, RosaQoL and PaGA were statistically significantly more improved in the Minocycline group than in the doxycycline group, and Minocycline 100 mg gives longer remission. In this study there was no significant difference in safety between these treatments; however, based on previous literature Minocycline has a lower risk-to-benefit ratio than doxycycline. Minocycline 100 mg may be a good alternative treatment for those patients who, for any reason, are unable or unwilling to take doxycycline 40 mg.
D C Van Rappard - One of the best experts on this subject based on the ideXlab platform.
-
domino doxycycline 40 mg vs Minocycline 100 mg in the treatment of rosacea a randomized single blinded noninferiority trial comparing efficacy and safety
British Journal of Dermatology, 2017Co-Authors: M. Van Der Linden, A R Van Ratingen, D C Van Rappard, Stella A. Nieuwenburg, Phyllis I SpulsAbstract:SummaryBackground There is a lack of evidence for Minocycline in the treatment of rosacea. Objectives To compare the efficacy and safety of doxycycline 40 mg vs. Minocycline 100 mg in papulopustular rosacea. Methods In this randomized, single-centre, 1 : 1 allocation, assessor-blinded, noninferiority trial, patients with mild-to-severe papulopustular rosacea were randomly allocated to either oral doxycycline 40 mg or Minocycline 100 mg for a 16-week period with 12 weeks of follow-up. Our primary outcomes were the change in lesion count and change in patient's health-related quality of life (using RosaQoL). Intention-to-treat and per protocol analyses were performed. Results Of the 80 patients randomized (40 Minocycline, 40 doxycycline), 71 were treated for 16 weeks. Sixty-eight patients completed the study. At week 16, the median change in lesion count was comparable in both groups: doxycycline vs. Minocycline, respectively 13 vs. 14 fewer lesions. The RosaQoL scores were decreased for both doxycycline and Minocycline, respectively by 0·62 and 0·86. Secondary outcomes were comparable except for Investigator's Global Assessment success, which was seen significantly more often in the Minocycline group than in the doxycycline group (60% vs. 18%, P < 0·001). At week 28, outcomes were comparable, except for RosaQoL scores and PaGA, which were significantly different in favour of Minocycline (P = 0·005 and P = 0·043, respectively), and fewer relapses were recorded in the Minocycline group than in the doxycycline group (7% and 48%, respectively; P < 0·001). No serious adverse reactions were reported. Conclusions Minocycline 100 mg is noninferior to doxycycline 40 mg in efficacy over a 16- week treatment period. At follow-up, RosaQoL and PaGA were statistically significantly more improved in the Minocycline group than in the doxycycline group, and Minocycline 100 mg gives longer remission. In this study there was no significant difference in safety between these treatments; however, based on previous literature Minocycline has a lower risk-to-benefit ratio than doxycycline. Minocycline 100 mg may be a good alternative treatment for those patients who, for any reason, are unable or unwilling to take doxycycline 40 mg.
